Aardvark Therapeutics — Third Quarter 2026 Earnings Summary

Aardvark Therapeutics received FDA approval to lift the clinical hold on its investigational drug ARD-101 for treating hyperphagia in Prader-Willi Syndrome, allowing the company to proceed with an open-label trial at a dose of 200 mg twice daily. The company plans to meet with the FDA in the first quarter of 2027 to finalize its clinical development strategy and expects to resume clinical activities in PWS during 2027. Financial results for the third quarter of 2026 showed a net loss of $19.2 million, with the company maintaining $60.3 million in cash and short-term investments to fund operations through 2027.